Stalking influenza by vaccination with pre-fusion headless HA mini-stem

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Valkenburg, Sophie A ^a,b   Mallajosyula, V Vamsee Aditya ^c   Li, Olive T W ^b   Chin, Alex W H ^b   Carnell, George ^d   Temperton, Nigel ^d   Varadarajan, Raghavan ^c   Poon, Leo L M ^b  

^a HKU PASTEUR RESEARCH CENTRE   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c INDIAN INSTITUTE OF SCIENCE   (India)

^d UNIVERSITY OF KENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ, AVIAN INFLUENZA A VIRUS; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY; PROTEIN BINDING; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; VIRUS ANTIBODY;

ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG STABILITY; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE INFECTIONS; PASSIVE IMMUNIZATION; PROTEIN FOLDING; PROTEIN MULTIMERIZATION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; DRUG STABILITY; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNIZATION, PASSIVE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN MULTIMERIZATION; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VACCINES, SYNTHETIC;

EID: 84960448072     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep22666     Document Type: Article

References (39)

1. Gerhard, W. The role of the antibody response in influenza virus infection. Curr Top Microbiol Immunol 260, 171-190 (2001).
2. Wu, Y., Tefsen, B., Shi, Y. & Gao, G. F. Bat-derived influenza-like viruses H17N10 and H18N11. Trends Microbiol 22, 183-191 (2014).
3. Skehel, J. J. & Wiley, D. C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 69, 531-569 (2000).
4. Skehel, J. J. & Wiley, D. C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 69, 531-569 (2000).
5. de Vries, R. D., Altenburg, A. F. & Rimmelzwaan, G. F. Universal influenza vaccines, science fiction or soon reality? Expert Rev Vaccines 14, 1299-1301 (2015).
6. Ellebedy, A. H. & Ahmed, R. Re-engaging cross-reactive memory B cells: the influenza puzzle. Front Immunol 3, 53 (2012).
7. Rathore, U., Kesavardhana, S., Mallajosyula, V. V. & Varadarajan, R. Immunogen design for HIV-1 and influenza. Biochim Biophys Acta 1844, 1891-1906 (2014).
8. Steel, J. et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 1 (2010).
9. Wei, C. J. et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329, 1060-1064 (2010).
10. Krammer, F., Pica, N., Hai, R., Margine, I. & Palese, P. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol 87, 6542-6550 (2013).
11. Krammer, F., Pica, N., Hai, R., Tan, G. S. & Palese, P. Hemagglutinin Stalk-Reactive Antibodies Are Boosted following Sequential Infection with Seasonal and Pandemic H1N1 Influenza Virus in Mice. Journal of virology 86, 10302-10307 (2012).
12. Mallajosyula, V. V. et al. Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection. Proc Natl Acad Sci USA 111, E2514-2523 (2014).
13. Mallajosyula, V. V. et al. Hemagglutinin Sequence Conservation Guided Stem Immunogen Design from Influenza A H3 Subtype. Front Immunol 6, 329 (2015).
14. Bommakanti, G. et al. Design of Escherichia coli-expressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge. J Virol 86, 13434-13444 (2012).
15. Impagliazzo, A. et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science (2015).
16. Yassine, H. M. et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med (2015).
17. O'Hagan, D. T., Ott, G. S., Nest, G. V., Rappuoli, R. & Giudice, G. D. The history of MF59((R)) adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines 12, 13-30 (2013).
18. Stevens, J. et al. Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science 312, 404-410 (2006).
19. Sharma, D. et al. Protein minimization of the gp120 binding region of human CD4. Biochemistry 44, 16192-16202 (2005).
20. Bommakanti, G. et al. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc Natl Acad Sci USA 107, 13701-13706 (2010).
21. Guthe, S. et al. Very fast folding and association of a trimerization domain from bacteriophage T4 fibritin. J Mol Biol 337, 905-915 (2004).
22. Ekiert, D. C. et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333, 843-850 (2011).
23. Corti, D. et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850-856 (2011).
24. Ekiert, D. C. et al. Antibody recognition of a highly conserved influenza virus epitope. Science 324, 246-251 (2009).
25. Sui, J. et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16, 265-273 (2009).
26. Goff, P. H. et al. Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies. PLoS One 8, e79194 (2013).
27. Wohlbold, T. J. et al. Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses. Vaccine 33, 3314-3321 (2015).
28. Schneemann, A. et al. A virus-like particle that elicits cross-reactive antibodies to the conserved stem of influenza virus hemagglutinin. J Virol 86, 11686-11697 (2012).
29. Whittle, J. R. et al. Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages. J Virol 88, 4047-4057 (2014).
30. DiLillo, D. J., Tan, G. S., Palese, P. & Ravetch, J. V. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat Med 20, 143-151 (2014).
31. Jegaskanda, S. et al. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J Immunol 190, 1837-1848 (2013).
32. Khurana, S. et al. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Sci Transl Med 5, 200ra114 (2013).
33. Mazanec, M. B., Coudret, C. L. & Fletcher, D. R. Intracellular neutralization of influenza virus by immunoglobulin A antihemagglutinin monoclonal antibodies. J Virol 69, 1339-1343 (1995).
34. Huang, Y., Niu, B., Gao, Y., Fu, L. & Li, W. CD-HIT Suite: a web server for clustering and comparing biological sequences. Bioinformatics 26, 680-682 (2010).
35. Higgins, D. G. & Sharp, P. M. CLUSTAL: a package for performing multiple sequence alignment on a microcomputer. Gene 73, 237-244 (1988).
36. Ganesh, C., Shah, A. N., Swaminathan, C. P., Surolia, A. & Varadarajan, R. Thermodynamic characterization of the reversible, twostate unfolding of maltose binding protein, a large two-domain protein. Biochemistry 36, 5020-5028 (1997).
37. Ferrara, F. et al. The human Transmembrane Protease Serine 2 is necessary for the production of Group 2 influenza A virus pseudotypes. J Mol Genet Med 7, 309-314 (2012).
38. Temperton, N. J. et al. A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. Influenza Other Respir Viruses 1, 105-112 (2007).
39. + T cells for heterosubtypic protection. Proceedings of the National Academy of Sciences of the United States of America 111, 5676-5681 (2014).